PhaseV Raises $15 Million to Push the Boundaries of ML for Clinical Trial Optimization
Healthcare IT Today
NOVEMBER 7, 2023
A recent Deloitte study estimates the average cost of developing a single new drug at $2.3 Moreover, the vast majority of drug candidates do not reach the finish line, and many fail the clinical phase even though the biology works. billion in 2022, with an average 7.1-year year deployment time.
Let's personalize your content